This page shows the latest Parvus news and features for those working in and with pharma, biotech and healthcare.
There has been a flurry of licensing deals in the coeliac disease area in recent months, including deals between GlaxoSmithKline and Sitari and Roche/Genentech and Parvus, as drugmakers eye a
Numerous other companies are investigating the potential of Tregs, including Genentech, which recently signed a deal with Parvus Therapeutics in autoimmune diseases.
Parvus’ Navacims are the brainchild of University of Calgary researcher Pere Santamaria, who was a founder of the biotech in 2009, and serves as its chief scientific officer. ... That’s very different approach to current autoimmune therapies that
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...